These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 21520632)

  • 1. [Bladder preservation using chemoradiation therapy for locally invasive bladder cancer].
    Abe T; Yoshioka T; Sato M; Mori N; Sekii K; Itatani H
    Nihon Hinyokika Gakkai Zasshi; 2011 Jan; 102(1):14-22. PubMed ID: 21520632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [OUTCOME OF BLADDER PRESERVATION USING LOW DOSE CHEMORADIATION THERAPY IN PATIENTS WITH LOCALLY INVASIVE BLADDER CANCER].
    Matsushita M; Kitakaze H; Okada K; Minato N; Mori N; Yoshioka T
    Nihon Hinyokika Gakkai Zasshi; 2018; 109(2):59-67. PubMed ID: 31006743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial results of retrospective study: preoperative transurethral excision plus chemotherapy and radiation therapy and trial of bladder preservation.
    Gamal El-Deen HS
    J Egypt Natl Canc Inst; 2007 Jun; 19(2):133-46. PubMed ID: 19034344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?
    Wo JY; Shipley WU; Dahl DM; Coen JJ; Heney NM; Kaufman DS; Zietman AL
    BJU Int; 2009 Jul; 104(2):179-83. PubMed ID: 19154448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bladder preservation by combined modality therapy for invasive bladder cancer.
    Kachnic LA; Kaufman DS; Heney NM; Althausen AF; Griffin PP; Zietman AL; Shipley WU
    J Clin Oncol; 1997 Mar; 15(3):1022-9. PubMed ID: 9060542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Initial conservative treatment for grade 3 Ta-1 superficial bladder cancer].
    Fujimoto K; Chihara Y; Kondo H; Hirao Y
    Hinyokika Kiyo; 2006 Jun; 52(6):433-8. PubMed ID: 16848356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response.
    Kaufman DS; Winter KA; Shipley WU; Heney NM; Chetner MP; Souhami L; Zlotecki RA; Sause WT; True LD
    Oncologist; 2000; 5(6):471-6. PubMed ID: 11110598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer.
    Shipley WU; Kaufman DS; Zehr E; Heney NM; Lane SC; Thakral HK; Althausen AF; Zietman AL
    Urology; 2002 Jul; 60(1):62-7; discussion 67-8. PubMed ID: 12100923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
    George L; Bladou F; Bardou VJ; Gravis G; Tallet A; Alzieu C; Serment G; Salem N
    Urology; 2004 Sep; 64(3):488-93. PubMed ID: 15351577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concurrent chemoradiotherapy for clinical stage T2 bladder cancer: report of a single institution.
    Peyromaure M; Slama J; Beuzeboc P; Ponvert D; Debré B; Zerbib M
    Urology; 2004 Jan; 63(1):73-7. PubMed ID: 14751352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined chemotherapy and radiation with selective organ preservation for muscle-invasive bladder carcinoma. A single-institution phase II study.
    Fellin G; Graffer U; Bolner A; Ambrosini G; Caffo O; Luciani L
    Br J Urol; 1997 Jul; 80(1):44-9. PubMed ID: 9240179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic overview of chemotherapy effects in urothelial bladder cancer.
    Nilsson S; Ragnhammar P; Glimelius B; Nygren P;
    Acta Oncol; 2001; 40(2-3):371-90. PubMed ID: 11441942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802.
    Tester W; Caplan R; Heaney J; Venner P; Whittington R; Byhardt R; True L; Shipley W
    J Clin Oncol; 1996 Jan; 14(1):119-26. PubMed ID: 8558186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A bladder preservation regimen using intra-arterial chemotherapy and radiotherapy for invasive bladder cancer: a prospective study.
    Miyanaga N; Akaza H; Okumura T; Sekido N; Kawai K; Shimazui T; Kikuchi K; Uchida K; Takeshima H; Ohara K; Akine Y; Ita Y
    Int J Urol; 2000 Feb; 7(2):41-8. PubMed ID: 10710246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction cisplatin and fluorouracil-based chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer.
    Lin CC; Hsu CH; Cheng JC; Huang CY; Tsai YC; Hsu FM; Huang KH; Cheng AL; Pu YS
    Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):442-8. PubMed ID: 19307067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bladder preservation multimodality therapy as an alternative to radical cystectomy for treatment of muscle invasive bladder cancer.
    Maarouf AM; Khalil S; Salem EA; ElAdl M; Nawar N; Zaiton F
    BJU Int; 2011 May; 107(10):1605-10. PubMed ID: 20825396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Invasive bladder cancer: a single-institution experience with bladder-sparing approach.
    Zapatero A; Martín de Vidales C; Marín A; Cerezo L; Arellano R; Rabadán M; Pérez-Torrubia A
    Int J Cancer; 2000 Oct; 90(5):287-94. PubMed ID: 11091353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy, and hyperfractionated radiotherapy: long term results.
    Danesi DT; Arcangeli G; Cruciani E; Altavista P; Mecozzi A; Saracino B; Orefici F
    Cancer; 2004 Dec; 101(11):2540-8. PubMed ID: 15481058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of high-risk non-muscle invasive bladder cancer.
    Brausi M; Olaru V
    Minerva Urol Nefrol; 2012 Dec; 64(4):255-60. PubMed ID: 23288212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitivity to chemoradiation predicts development of metastasis in muscle-invasive bladder cancer patients.
    Koga F; Numao N; Saito K; Masuda H; Fujii Y; Kawakami S; Kihara K
    Urol Oncol; 2013 Oct; 31(7):1270-5. PubMed ID: 22386622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.